Ward Sarah A, Macharia Annliz, Hacker Michele R, Elkadry Eman A, Winkelman William D
Department of Obstetrics and Gynecology, Mount Auburn Hospital, Cambridge, MA, USA.
Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Int Urogynecol J. 2025 Apr;36(4):849-855. doi: 10.1007/s00192-025-06080-7. Epub 2025 Mar 1.
Achieving adequate pain relief is crucial for intradetrusor onabotulinumtoxinA treatments for idiopathic overactive bladder in office settings. The objective of this study was to determine whether buffered lidocaine bladder instillation provides better pain control than standard lidocaine prior to intradetrusor onabotulinumtoxinA injections.
We conducted a prospective, double-blind, randomized controlled trial comparing two protocols. The standard protocol used a pre-procedure instillation of 50 ml of 1% lidocaine and 50 ml of 0.9% saline. The buffered lidocaine protocol used 50 ml of 1% lidocaine, 45 ml of 0.9% saline, and 5 ml of 8.4% sodium bicarbonate. Both protocols were administered 20 min before onabotulinumtoxinA injections. Female patients with a primary diagnosis of idiopathic overactive bladder were randomized. The primary outcome was procedural pain using a visual analog scale (VAS) measured in millimeters, with secondary outcomes of patient satisfaction and willingness to repeat the procedure.
Of the 76 patients enrolled, 38 were randomized to each group. Data were analyzed for 37 patients in the buffered lidocaine group, and 36 in the standard lidocaine group. Both groups had comparable baseline characteristics. There was no difference in median pain measured by VAS between the buffered (16 [9-40]) and standard (25 [15-55]) protocols (p = 0.21). The buffered group reported a higher, though not statistically significant, satisfaction rate (68% vs 39%, p = 0.08).
Intradetrusor onabotulinumtoxinA injections are generally well tolerated among women with idiopathic overactive bladder. No difference was found between protocols, suggesting that buffered lidocaine instillation may not improve pain control among women with idiopathic overactive bladder, although we had insufficient power to detect a difference of the observed magnitude.
在门诊环境中,对于特发性膀胱过度活动症患者进行膀胱逼尿肌内注射A型肉毒毒素治疗时,实现充分的疼痛缓解至关重要。本研究的目的是确定在膀胱逼尿肌内注射A型肉毒毒素之前,缓冲利多卡因膀胱灌注是否比标准利多卡因能提供更好的疼痛控制。
我们进行了一项前瞻性、双盲、随机对照试验,比较两种方案。标准方案在操作前灌注50毫升1%利多卡因和50毫升0.9%生理盐水。缓冲利多卡因方案使用50毫升1%利多卡因、45毫升0.9%生理盐水和5毫升8.4%碳酸氢钠。两种方案均在注射A型肉毒毒素前20分钟给药。将原发性诊断为特发性膀胱过度活动症的女性患者随机分组。主要结局是使用视觉模拟量表(VAS)以毫米为单位测量的操作疼痛,次要结局是患者满意度和重复该操作的意愿。
在纳入的76例患者中,每组随机分配38例。对缓冲利多卡因组的37例患者和标准利多卡因组的36例患者的数据进行了分析。两组具有可比的基线特征。缓冲方案(16[9 - 40])和标准方案(25[15 - 55])之间通过VAS测量的中位疼痛无差异(p = 0.21)。缓冲组报告的满意度较高,尽管无统计学意义(68%对39%,p = 0.08)。
膀胱逼尿肌内注射A型肉毒毒素在特发性膀胱过度活动症女性中通常耐受性良好。两种方案之间未发现差异,这表明缓冲利多卡因灌注可能无法改善特发性膀胱过度活动症女性的疼痛控制,尽管我们没有足够的效能检测到所观察到的差异幅度。